Beyond Air, Inc., a medical device and biopharmaceutical company focused on developing inhaled nitric oxide for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide for the treatment of solid tumors, announced that it will report financial results for its first fiscal quarter ended June 30, 2022 on Thursday, August 11, 2022.
July 27, 2022
· 5 min read